Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Follow-Up Questions
What is the price performance of ENLV stock?
The current price of ENLV is $1.04, it has decreased 0.66% in the last trading day.
What are the primary business themes or industries for Enlivex Therapeutics Ltd?
Enlivex Therapeutics Ltd belongs to Biotechnology industry and the sector is Health Care
What is Enlivex Therapeutics Ltd market cap?
Enlivex Therapeutics Ltd's current market cap is $24.8M
Is Enlivex Therapeutics Ltd a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Enlivex Therapeutics Ltd, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell
